

SUGEN

[View the current SUGEN Page on BioPortfolio.com](http://www.bioportfolio.com)

(<http://www.bioportfolio.com/biocorporate/9469-SUGEN.html>)

Contact Details:

230 E. Grand Ave
South San Francisco
CA
94080
United States of America

Tel: 650 553 8741
Fax: 650 553 8348
Email:

SUGEN is a biopharmaceutical company focused on the discovery and development of small molecule drugs which target specific cellular signal transduction pathways. These signalling pathways are regulated by cell-surface receptors or intracellular signalling molecules known as tyrosine kinases ("TKs"), tyrosine phosphatases ("TPs") and serine-threonine kinases ("STKs"), three of the largest known families of receptors in the body and key regulators of critical cellular functions. Aberrant signalling of TKs, TPs and STKs has been shown to result in a variety of chronic and acute pathological diseases, including cancer and diabetes as well as in dermatologic, ophthalmic, neurologic and immune disorders. The Company believes that compounds designed to target certain kinases and phosphatases and inhibit enzyme activity or prevent the binding of downstream signalling molecules make attractive therapeutic product candidates.

Recent Publications by SUGEN:



- [Effect of Terminalia arjuna extract on adriamycin-induced DNA damage.](#)
*The effect of a bark extract of Terminalia arjuna (TAE) was studied on the...*19th December, 2008
Division of Cancer Biology, Sugem Life Sciences, Tirupati, 517505, AP,- *Phytother Res.* 2008 Sep;22(9):1188-94. ([DOI Direct Link](#))
- [High-performance liquid chromatographic method for determination of reversible isomers of SU5416.](#)
*SU5416 shows light-induced reversible geometric isomerism. A simple,...*29th June, 2006
Formulations Research, SUGEN Inc., 230 S. Grand Avenue, South San- *J Chromatogr A.* 2006 Mar 31;1110(1-2):73-80. Epub 2006 Feb 10. ([DOI Direct Link](#))
- [Simultaneous determination of Z-3-\[\(2,4-dimethylpyrrol-5-yl\)methylidene\]-2-indolinone \(SU5416\) and its interconvertible geometric isomer \(SU5886\) in rat plasma by LC/MS/MS.](#)
*Z-3-[(2,4-Dimethylpyrrol-5-yl)methylidene]-2-indolinone (SU5416) is a...*23rd May, 2006
Department of Bioanalysis and Pharmacokinetics, Sugem, 230 E. Grand Ave.,- *J Pharm Biomed Anal.*

- 2005 Jul 1;38(3):479-86. Epub 2005 Mar 2. ([DOI Direct Link](#))
- [PAK4 mediates morphological changes through the regulation of GEF-H1.](#)
*Precise spatial and temporal regulation of Rho GTPases is required in...*20th September, 2005
 SUGEN Incorporated, 230 East Grand Avenue, South San Francisco, CA 94080,- J Cell Sci. 2005 May 1;118(Pt 9):1861-72. Epub 2005 Apr 12. ([DOI Direct Link](#))
 - [Transcriptional-based screens for pathway-specific, high-throughput target discovery in endothelial cells.](#)
*With the sequence of the human genome at hand, target discovery strategies...*13th May, 2005
 SUGEN, Inc.,- J Biomol Screen. 2004 Dec;9(8):704-11. ([DOI Direct Link](#))
 - [Troglitazone induces a rapid drop of mitochondrial membrane potential in liver HepG2 cells.](#)
*Troglitazone, a thiazolidinedione containing compound, was widely used to...*11th February, 2005
 Drug Discovery, SUGEN, Inc., 230 East Grand Avenue, South San Francisco,- Toxicol Lett. 2005 Jan 15;155(1):41-50. ([DOI Direct Link](#))
 - [Simultaneous determination of Z-SU5416 and its interconvertible geometric E-isomer in rat plasma by LC/MS/MS.](#)
*SU5416 is a selective inhibitor of vascular endothelial growth factor...*28th December, 2004
 Department of Bioanalysis, Metabolism and Pharmacokinetics, SUGEN Inc., 230- J Pharm Biomed Anal. 2004 May 28;35(3):513-22. ([DOI Direct Link](#))
 - [An automated image capture and quantitation approach to identify proteins affecting tumor cell proliferation.](#)
*To facilitate the characterization of proteins that negatively regulate...*5th November, 2004
 Target Discovery Department, Sugen, Inc. (A Subsidiary of Pfizer), South- J Biomol Screen. 2004 Apr;9(3):216-22. ([DOI Direct Link](#))
 - [The mouse kinome: discovery and comparative genomics of all mouse protein kinases.](#)
*We have determined the full protein kinase (PK) complement (kinome) of...*30th September, 2004
 SUGEN, Incorporated, 230 East Grand Avenue, South San Francisco, CA 94025,- Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11707-12. Epub 2004 Aug 2. ([DOI Direct Link](#))
 - [The oxidative mechanism of action of ortho-quinone inhibitors of protein-tyrosine phosphatase alpha is mediated by hydrogen peroxide.](#)
*Here, we report the identification and characterization of five...*8th September, 2004
 Drug Discovery, SUGEN Inc., 230 East Grand Avenue, South San Francisco, CA- Arch Biochem Biophys. 2004 Sep 1;429(1):30-41. ([DOI Direct Link](#))
 - [Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.](#)
*Acute myeloid leukemia (AML) is associated with dysregulated hematopoietic...*23rd July, 2004
 Sugen Inc., South San Francisco, CA, USA.- Leuk Res. 2004 Jul;28(7):679-89. ([DOI Direct Link](#))
 - [Powder-in-bottle formulation of SU011248. Enabling rapid progression into human clinical trials.](#)
*SU011248 is an oral, multitargeted receptor tyrosine kinase inhibitor...*15th June, 2004
 Sugen Inc. (a Pharmacia Company), S. San Francisco, California, USA.- Drug Dev Ind Pharm. 2004 Jan;30(1):19-25. ([DOI Direct Link](#))
 - [Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor.](#)
*Biomarkers that indicate biological activity and/or efficacy are a...*19th March, 2004
 Department of Preclinical Research and Exploratory Development, SUGEN,- Oncogene. 2004 Feb 26;23(8):1618-26. ([DOI Direct Link](#))

Press Releases on

SUGEN:

8th
July,
2008

Longitude
Capital

MENLO
PARK, Calif.,
July 8
/PRNewswire/
-- Longitude
Capital today
announced
the closing of
its first
investment
vehicle,
Longitude
Venture
Partners, L.P.
(the "Fund"),
a \$325 million

[Longitude](#)

[Capital](#)

[BioNews Results for SUGEN](#)

[\\$325](#)

[Million](#)

[Life](#)

[Sciences](#)

[Fund](#)

- [Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer](#)

Pharma Live: Sep 4 2009 12:33PM Matching: sugen

- [Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer](#)

PR Newswire: Sep 4 2009 12:23PM Matching: sugen

- [Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer](#)

PR Newswire via Yahoo!: Sep 4 2009 12:17PM Matching: sugen

- [Kolltan Pharmaceuticals Expands Board of Directors and Senior Executive Team](#)

Pharma Live: Aug 18 2009 5:50PM Matching: sugen



SUGEN Clinical Trials:



- [Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma](#)



SUGEN Patents:

- 6706709- [Indolinone derivatives as protein kinase/phosphatase inhibitors](#)
- 6861442- [PYK2 and inflammation](#)
- 6878733- [Formulations for pharmaceutical agents ionizable as free acids or free bases](#)
- 6906093- [Indolinone combinatorial libraries and related products and methods for the treatment of disease](#)
- 6908930- [4-substituted 7-AZA-indolin-2-ones and their use as protein kinase inhibitors](#)
- 6908984- [Megakaryocytic protein tyrosine kinase I](#)
- 6911446- [Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds](#)
- 6987113- [Tyrosine kinase inhibitors](#)
- 7029912- [Tyrosine kinase substrate\(Tks\) proteins](#)
- 7037677- [Megakaryocytic protein tyrosine kinase I](#)
- 7037909- [Tetracyclic compounds as c-Met inhibitors](#)
- 6861418- [4-aryl substituted indolinones](#)
- 6855730- [3-methylidene-2-indolinone modulators of protein kinase](#)
- 6849641- [Azaindole tyrosine kinase inhibitors](#)
- 6710067- [Mannich base prodrugs of 3-\(pyrrol-2-ylmethylidene\)-2-indolinone derivatives](#)
- 6716575- [Diagnosis and treatment of AUR1 and/or AUR2 related disorders](#)
- 6716870- [Prodrugs of 3-\(pyrrol-2-ylmethylidene\)-2-indolinone derivatives](#)
- 6750240- [Methods of using bis-indolylquinones](#)
- 6777417- [3-\(4,5,6,7-tetrahydroindol-2-ylmethylidene\)-2-indolinone derivatives as kinase inhibitors](#)
- 6797725- [Prodrugs of a 3-\(pyrrol-2-ylmethylidene\)-2-indolinone derivatives](#)
- 6818440- [Diagnosis and treatment of alk-7 related disorders](#)
- 6841579- [Diagnosis and treatment of AUR1 and/or AUR2 related disorders](#)
- 6844177- [Diagnosis and treatment of PTP04 related disorders](#)
- 6846839- [Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis](#)
- 7053086- [4-heteroaryl-3-heteroarylidene-2-indolinones and their use as protein kinase inhibitors](#)
- 7053113- [Mannich base prodrugs of 3-\(pyrrol-2-yl-methylidene\)-2-indolinone derivatives](#)
- 7202265- [Indolinone combinatorial libraries and related products and methods for the treatment of disease](#)
- 7211600- [Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds](#)
- 7214700- [\(2-Oxindol-3-ylidene\) acetic acid derivatives and their use as protein kinase inhibitors](#)
- 7217737- [Method and compositions for inhibiting cell proliferative disorders](#)
- 7230098- [Aminoheteroaryl compounds as protein kinase inhibitors](#)
- 7250417- [Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors](#)
- 7256189- [3-\(4-amidopyrrol-2-ylmethylidene\)-2-indolinone derivatives as protein kinase inhibitors](#)
- 7320996- [Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer](#)
- 7439329- [GEF-H1b: biomarkers, complexes assays and therapeutic uses thereof](#)
- 7572924- [Pyrrole substituted 2-indolinone protein kinase inhibitors](#)
- 7189721- [Bicyclic protein kinase inhibitors](#)
- 7186832- [Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors](#)
- 7186716- [3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors](#)

- 7053114- [Prodrugs of a 3-\(pyrrol-2-ylmethylidene\)-2-indolinone derivatives](#)
- 7071332- [Indolinone derivatives as protein kinase/phosphatase inhibitors](#)
- 7105562- [Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein tyrosine kinase inhibitors](#)
- 7109185- [Pharmaceutical formulations comprising indolinone derivatives](#)
- 7115710- [Diagnosis and treatment of PTP related disorders](#)
- 7119090- [Pyrrole substituted 2-indolinone protein kinase inhibitors](#)
- 7119174- [Diagnosis and treatment of AUR1 and/or AUR2 related disorders](#)
- 7122548- [Triazolotriazine compounds and uses thereof](#)
- 7157460- [Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors](#)
- 7157577- [5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors](#)
- 7582756- [3-\(4-amidopyrrol-2-ylmethylidene\)-2-indolinone derivatives as protein kinase inhibitors](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10
Copyright 1997-2009 - BioPortfolio Limited.

